Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
NCT03136146 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42
Last updated 2026-02-17
Summary
This phase II trial studies the side effects and how well combination chemotherapy works in treating patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, Burkitt lymphoma/leukemia, or double-hit lymphoma/leukemia that has come back or does not respond to treatment. Drugs used in chemotherapy, such as clofarabine, etoposide, cyclophosphamide, vincristine sulfate liposome, dexamethasone and bortezomib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Conditions
- Recurrent Acute Lymphoblastic Leukemia
- Recurrent Adult Lymphoblastic Lymphoma
- Recurrent Burkitt Leukemia
- Recurrent Burkitt Lymphoma
- Recurrent Childhood Lymphoblastic Lymphoma
- Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Refractory Acute Lymphoblastic Leukemia
- Refractory Burkitt Leukemia
- Refractory Burkitt Lymphoma
- Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
- Refractory Lymphoblastic Lymphoma
Interventions
- DRUG
-
Vincristine Sulfate Liposome
Given IV
- BIOLOGICAL
-
Given IV
- DRUG
-
Given SC
- DRUG
-
Clofarabine
Given IV
- DRUG
-
Given IV
- DRUG
-
Given IV or PO
- DRUG
-
Etoposide
Given IV
- BIOLOGICAL
-
Ofatumumab
Given IV
- BIOLOGICAL
-
Given SC
Sponsors & Collaborators
-
National Cancer Institute (NCI)
collaborator NIH -
M.D. Anderson Cancer Center
lead OTHER
Principal Investigators
-
Maro Ohanian · M.D. Anderson Cancer Center
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 15 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-08-09
- Primary Completion
- 2027-08-01
- Completion
- 2027-08-01
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
NCT04161248 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
NCT00002494 ·Status: COMPLETED ·Phase: PHASE2
-
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
NCT02213913 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
NCT01769209 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
NCT00006125 ·Status: COMPLETED ·Phase: PHASE2
-
Epirubicin and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT00062296 ·Status: COMPLETED ·Phase: PHASE2
-
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
NCT03113500 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT02538926 ·Status: WITHDRAWN ·Phase: PHASE2
-
Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
NCT00068315 ·Status: COMPLETED ·Phase: PHASE1
-
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
NCT00001337 ·Status: COMPLETED ·Phase: PHASE2
-
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
NCT03023046 ·Status: COMPLETED ·Phase: PHASE2
-
Adding Targeted Drugs to Usual Chemotherapy for Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LBL)
NCT06210750 ·Status: WITHDRAWN ·Phase: PHASE2
-
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
NCT02436707 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
NCT00601718 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
NCT00039130 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
NCT00513955 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)
NCT00823719 ·Status: COMPLETED ·Phase: PHASE2
-
Combination Chemotherapy in Treating Patients With AIDS-Related Lymphoma
NCT00003388 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
NCT06624085 ·Status: RECRUITING ·Phase: PHASE1
-
Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT01555541 ·Status: COMPLETED ·Phase: PHASE2
-
Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma
NCT03704714 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2
-
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia
NCT02153580 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma
NCT02561273 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
NCT00005977 ·Status: COMPLETED ·Phase: PHASE3
-
Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL
NCT02393157 ·Status: RECRUITING ·Phase: PHASE2